A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor

Documenti analoghi

• Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants
  di: Pharavee Jaiprasart, et al.
  Pubblicazione: (2024)
• Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations
  di: Wei Zhu, et al.
  Pubblicazione: (2024)
• Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial
  di: Gerard Greig, et al.
  Pubblicazione: (2026)
• Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
  di: Aravind Mittur, et al.
  Pubblicazione: (2026)
• Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
  di: Katharina Erb‐Zohar, et al.
  Pubblicazione: (2024)